Mohit Kaushal Sells 38,433 Shares of Oncology Institute (NASDAQ:TOI) Stock

The Oncology Institute, Inc. (NASDAQ:TOI) Director Mohit Kaushal sold 38,433 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $3.50, for a total value of $134,515.50. Following the completion of the transaction, the director directly owned 172,583 shares in the company, valued at approximately $604,040.50. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mohit Kaushal also recently made the following trade(s):

• On Tuesday, April 14th, Mohit Kaushal sold 57,286 shares of Oncology Institute stock. The shares were sold at an average price of $3.50, for a total value of $200,501.00.

Oncology Institute Trading Up 3.2%

TOI stock traded up $0.11 during trading hours on Thursday, hitting $3.54. 2,190,265 shares of the stock traded hands, compared to its average volume of 1,548,966. The stock has a 50-day simple moving average of $2.95 and a 200 day simple moving average of $3.38. The Oncology Institute, Inc. has a one year low of $1.91 and a one year high of $4.88. The company has a market cap of $349.89 million, a P/E ratio of -6.32 and a beta of 0.17.

Oncology Institute (NASDAQ:TOI) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The business had revenue of $141.96 million during the quarter, compared to analysts’ expectations of $139.78 million.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TOI. Josh Arnold Investment Consultant LLC increased its holdings in shares of Oncology Institute by 1,104.3% in the fourth quarter. Josh Arnold Investment Consultant LLC now owns 2,459,809 shares of the company’s stock worth $8,757,000 after purchasing an additional 2,255,559 shares during the period. CenterBook Partners LP increased its stake in Oncology Institute by 277.8% in the third quarter. CenterBook Partners LP now owns 2,704,650 shares of the company’s stock valued at $9,439,000 after acquiring an additional 1,988,751 shares during the last quarter. Kanen Wealth Management LLC bought a new position in Oncology Institute in the third quarter valued at $6,421,000. Marshall Wace LLP bought a new position in Oncology Institute in the second quarter valued at $3,028,000. Finally, Geode Capital Management LLC increased its stake in Oncology Institute by 231.7% in the second quarter. Geode Capital Management LLC now owns 1,279,443 shares of the company’s stock valued at $2,623,000 after acquiring an additional 893,696 shares during the last quarter. Institutional investors own 36.86% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on TOI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncology Institute in a report on Wednesday, January 21st. B. Riley Financial raised their target price on Oncology Institute from $6.00 to $8.00 and gave the company a “buy” rating in a report on Friday, March 13th. Needham & Company LLC reaffirmed a “buy” rating and set a $5.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Finally, BTIG Research reissued a “buy” rating and issued a $7.00 price objective on shares of Oncology Institute in a research report on Monday, March 9th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.00.

Oncology Institute Company Profile

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.